Get started
Author

Julia Calzas

Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer
2018 · Andrés J. Muñoz Martín, Israel Ortega, et al. · British Journal of Cancer · 141
Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer.
1997 · R García-Carbonero, M Hidalgo, et al. · Journal of Clinical Oncology · 84
A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts
2023 · Andrés Muñoz, Cihan Ay, et al. · Journal of Clinical Oncology · 70
PDF
Incidence, predictors and prognostic significance of thromboembolic disease in patients with advancedALK-rearranged non-small cell lung cancer
2018 · Jon Zugazagoitia, Mercedes Biosca, et al. · European Respiratory Journal · 44
PDF
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
2021 · Fernando Franco, Enric Carcereny, et al. · PLoS ONE · 39
PDF
A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer
1998 · D. Castellano, P. Lianes, et al. · Annals of Oncology · 38
PDF
Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer
2017 · Israel Manzanedo, Fernando Pereira, et al. · Minerva Obstetrics and Gynecology · 16
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
2022 · Mariano Provencio, Manuel Cobo, et al. · BMC Cancer · 15
Multicenter study correlating molecular characteristics and clinical outcomes of cancer cases with patient-derived organoids
2025 · Paloma Navarro, Tatiana P. Grazioso, et al. · Journal of Experimental & Clinical Cancer Research · 14
PDF
Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO)
2020 · María Jesús Rubio, María José Lecumberri, et al. · Gynecologic Oncology Reports · 13
PDF
The use of cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer: a comparative study
2019 · I. Manzanedo, F. Pereira, et al. · Clinical & Translational Oncology · 12
Corazón y neoplasias
1998 · Julia Calzas, Pilar Lianes, et al. · Revista Española de Cardiología · 12
Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study
2022 · Alfonso Yubero, Aranzazu Barquín, et al. · BMC Cancer · 11
Long-Term Follow-Up of an Anthracycline-Containing Metronomic Chemotherapy Schedule in Advanced Breast Cancer
2009 · Enrique González-Billalabeitia, Julia Calzas, et al. · The Breast Journal · 11
[Indirect identification of hypersensitivity reaction to etoposide mediated by polysorbate 80].
2018 · Carmen Pantín, Javier Letellez, et al. · PubMed · 7
Condronecrosis laríngea tras radioterapia y quimioterapia concurrentes
2008 · Mónica Hernando, Ana Hernando, et al. · Acta Otorrinolaringológica Española · 5
Laryngeal Chondronecrosis Following Radiotherapy and Concurrent Chemotherapy
2008 · Mónica Hernando, Ana Hernando, et al. · Acta Otorrinolaringologica (English Edition) · 4
Cancer-associated venous thromboembolism and its impact on survival in the ONCOTHROMB12-01 cohort study
2025 · Bárbara Lobato-Delgado, Magdalena Ruiz, et al. · IJC Heart & Vasculature · 3
Life-threatening adverse drug reaction to paclitaxel. Postmarketing surveillance
2006 · A. Ruiz-Casado, J. Calzas, et al. · Clinical & Translational Oncology · 3
Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry
2024 · Enric Carcereny, Delvys Rodriguez-Abreu, et al. · Clinical & Translational Oncology · 1
PDF
Clinical experience with rucaparib after prior PARPi treatment: A subanalysis from the rucaparib access program in Spain by GEICO.
2022 · Alfonso Yubero-Esteban, Piedad Reche-Molina, et al. · Journal of Clinical Oncology · 1
403 Analysis of the clinical experience within rucaparib’s early access program in Spain – a GEICO study
2021 · A. Yubero-Esteban, A. Barquin, et al. · International Journal of Gynecological Cancer · 1
PDF
Spanish registry of thoracic tumors (TTR): Interim analyses of comorbidities, risk associations, personal and family history of cancer
2019 · R. Lopez Castro, P. Lianes, et al. · Annals of Oncology · 1
PB0931 Long-Term Performance of a Clinical-Genetic Risk Score of Venous Thromboembolism (VTE) in Cancer Patients
2023 · A. Muñoz Martín, M. Ruiz, et al. · Research and Practice in Thrombosis and Haemostasis
2022-RA-466-ESGO Long-term responders (LTR) to rucaparib in recurrent ovarian cancer: a sub-group analysis from the rucaparib access (RAP) program in Spain by GEICO
2022 · Alfonso Yubero, Aranzazu Barquín, et al. · International Journal of Gynecological Cancer
PDF
Works count: 37
Citation count: 546
H-index: 12
I10-index: 14
Year
Topic
Type